SCHEMBL7101780

SCHEMBL7101780

O=S(=O)(c1cc(Cl)cc(Cl)c1)N(c1cccc(NC(=S)Nc2cccc3ccccc23)c1)S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.52
KMT2A Q03164 5/20 0.51
MEN1 O00255 3/20 0.51
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 5/20 0.48
MAPT P10636 3/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KDM4E B2RXH2 2/20 0.48
HTT P42858 2/20 0.48
BLM P54132 2/20 0.48
NOD2 Q9HC29 1/20 0.48
NPC1 O15118 1/20 0.47
HPGD P15428 2/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
DUSP3 P51452 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10514431 0.78 RAB9A (0.69) GAAKMT2AMEN1RAB9AALDH1A1
SCHEMBL7518000 0.75 LMNA (0.52) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL7522388 0.75 MAPT (0.57) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL11072641 0.71 KMT2A (0.73) GAAKMT2AMEN1RAB9AALDH1A1
SCHEMBL7103879 0.71 MAPT (0.50) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL7103484 0.71 MEN1 (0.52) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL31206215 0.71 KMT2A (0.77) GAAKMT2AMEN1RAB9AALDH1A1
SCHEMBL8956204 0.71 KMT2A (0.77) GAAKMT2AMEN1RAB9AALDH1A1
SCHEMBL1275812 0.69 KMT2A (0.72) GAAKMT2AMEN1RAB9AALDH1A1
SCHEMBL7513281 0.68 HTR2C (0.47) KMT2AMEN1RAB9AALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1339668-A2 BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS GUILFORD PHARMACEUTICALS INC. (US) 2003-09-03 EP claimed
US-20020127605-A1 Bisubstituted carbocyclic cyclophilin binding compounds and their use GUILFORD PHARMACEUTICALS, INC. 2002-09-12 US claimed
WO-2002044126-A2 BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS GUILFORD PHARMACEUTICALS INC. (US) 2002-06-06 WO claimed
US-20020127605-A1 Bisubstituted carbocyclic cyclophilin binding compounds and their use GUILFORD PHARMACEUTICALS, INC. 2002-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020127605-A1 Bisubstituted carbocyclic cyclophilin binding compounds and their use PPIG, PIN1, PPIH GAA 1627/4885KMT2A 4656/4885MEN1 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.